Totally agree! As I should have said their attention for Actipatch is focused on more clearances and OEM partnerships. The RecoveryRX is all 'theirs' and THAT is also where their attention is now focused on due to OEMS selling and marketing the Actipatch in the USA. This is where we will see how successful KN is as sales manager. As I have stated numerous times on both boards, IMO the RX could and should be the monster in all this. I'm betting he shows his worth and he and RRX sales force reps get these products in major hospitals and used post operative, throughout the world.
(3)
(0)
BioElectronics Corporation (BIEL) Stock Research Links